US Patent

US10117848 — Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof

Method of Use · Assigned to Milestone Pharmaceuticals Inc · Expires 2036-04-13 · 10y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects highly water-soluble salts of a phenylalkylamine calcium channel blocker and their use in treating stable angina, migraine, and cardiac arrhythmia.

USPTO Abstract

The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4370

Patent Metadata

Patent number
US10117848
Jurisdiction
US
Classification
Method of Use
Expires
2036-04-13
Drug substance claim
No
Drug product claim
Yes
Assignee
Milestone Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.